A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR(60 mg QD and 90 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD)
Phase of Trial: Phase III
Latest Information Update: 09 Jun 2013
At a glance
- Drugs Dexlansoprazole (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Sponsors Takeda
- 24 Mar 2009 Actual patient number (908) added as reported by ClinicalTrials.gov.
- 02 Jul 2007 Status change from in progress to completed
- 31 Dec 2005 New trial record.